James E. Bradner - 06 May 2025 Form 4 Insider Report for AMGEN INC (AMGN)

Reporting relationship: EVP, R&D, & Chief Sci. Officer
Issuer ticker: AMGN
Reported as of: 06 May 2025
Net transaction value: +$6,204,975
SEC form: 4
Accepted by SEC: 08 May 2025, 20:49:53 UTC
Prior SEC filing: 09 May 2024
Next SEC filing: 10 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ James E. Bradner

Key filing fact

James E. Bradner filed Form 4 for AMGEN INC (AMGN) on 08 May 2025.

Key facts

This page summarizes James E. Bradner's Form 4 filing for AMGEN INC (AMGN).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 May 2025, 20:49.

Change

Previous filing in this sequence was filed on 09 May 2024.
Current net transaction value: +$6,204,975.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002005159 Primary reporting owner

Bradner James E.

Relationship: EVP, R&D, & Chief Sci. Officer
Address: ONE AMGEN CENTER DRIVE, THOUSAND OAKS
Signature: /s/ James E. Bradner
Signature date: 08 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMGN transaction

Common Stock

Award

Transaction value: $0
Shares: +3,549
Change %: +14%
Price: $0.000000
Shares after: 29,753
Date: 06 May 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMGN transaction Derivative

Nqso (Right to Buy)

Award

Transaction value: $6,204,975
Shares: +22,944
Change %
Price: $270.44
Shares after: 22,944
Date: 06 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,944
Exercise price: $270.44
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/6/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

Footnote F2

These shares include 948 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Footnote F3

These non-qualified stock options were granted pursuant to the Equity Incentive Plan and are exercisable in four equal annual installments of 25% each commencing on 5/6/2026.